Peer-reviewed veterinary case report
Liposomal clodronate reduces tumor macrophages in dogs
By Guth, A M et al.·Published in Veterinary and comparative oncology·2013·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma.
- Species:
- dog
Plain-English summary
A group of 13 dogs with soft-tissue sarcoma (a type of cancer) received a treatment called liposomal clodronate to see if it could help reduce the number of cancer-associated immune cells known as macrophages. The treatment was well tolerated, and initial results showed a significant decrease in these macrophages in tumor samples from some of the dogs. Additionally, levels of a protein linked to inflammation were also reduced. While more research is needed, these findings suggest that liposomal clodronate may be a promising option for managing this type of cancer in dogs.
People also search for: dog soft-tissue sarcoma treatment · liposomal clodronate for dogs · cancer in dogs macrophage treatment
Abstract
Increased numbers of tumour-associated macrophages correlate with rapid tumour growth and metastasis in tumours. Thus, macrophage depletion has potential as a novel cancer therapy and positive responses have been reported in rodent tumour models. To investigate the effectiveness of this approach in dogs with cancer, we evaluated the effects of the macrophage-depleting agent liposomal clodronate (LC) in dogs with soft-tissue sarcoma (STS). To this end, we conducted a clinical trial of LC therapy in 13 dogs with STS. Repeated LC administration was well tolerated clinically. Preliminary examination of tumour biopsy sets from 5 of the 13 dogs demonstrated that the density of CD11b(+) macrophages was significantly decreased after LC treatment. Circulating concentrations of interleukin-8 were also significantly reduced. These preliminary studies are the first to suggest that LC can be used as a systemic macrophage-depleting agent in dogs to reduce numbers of tumour-associated macrophages.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22540967/